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Summary. Diabetic patients under multiple injec-
tion insulin therapy (i.e., intensified insulin thera-
py, IIT) usually start this treatment during hospi-
talization. We report here on the logistics, efficacy, 
and safety of IIT, started in outpatients. Over 8 
months, 52 type I and type 11 diabetics were fol-
lowed up whose insulin regimens consecutive1y had 
been changed from conventional therapy to IIT. 
Two different IIT strategies were compared: free 
mixtures of regular and intermediate (12 hrs)-act-
ing insulin versus the basal and prandial insulin 
treatment with preprandial injections of regular in-
sulin, and ultra1ente (24 hrs-acting) or intermediate 
insulin for the basal demand. After 8 months 
HbA1 levels had decreased from 10.6% ±2.4% to 
8.0%±1.3% (means±SD). There was no differ-
ence between the two regimens with respect to met-
abolie control; but type 11 patients maintained the 
lowered HbA1 levels better than type I patients. 
Only two patients were hospitalized during the fol-
low-up time because of severe hypoglycemia. An 
increase of body weight due to the diet liberaliza-
tion during IIT became a problem in one-third of 
the patients. Our results suggest that outpatient 
initiation of IIT is safe and efficacious with respect 
to near-normoglycemic contro!. Weight control 
may become a problem in IIT patients. 
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In recent years, new approaches in the treatment 
of insulin-dependent diabetes mellitus (IDDM) 
have been deve10ped in order to achieve near-nor-
moglycemia. New devices for insulin injections 
(e.g., insulin pens) [2] can be used, which might 
Abbreviations: BPIT = basal and prandial insulin therapy; 
FMIT=free mixture insulin therapy; IIT=intensified insulin 
therapy 
enhance patients' motivation to prefer multiple in-
jection therapy (i.e., the intensified insulin therapy) 
to conventional regimens [11]. 
Insulin regimens are usually initiated or 
changed during hospitalization, in order to control 
strict1y the metabolie instabilities of the initiation 
period [10]. Nevertheless, there are some argu-
ments in favor of chan ging insulin therapy on an 
outpatient basis: insulin requirements are adapted 
much faster to the patient's usual way of life, 
especially with regard to physical activities, and 
to the normal diet. Furthermore, the costs of an 
outpatient treatment are much lower compared 
with hospitalization. 
The aim of our study was to evaluate the man-
agement and efficacy of an outpatient initiation 
of intensified insulin therapy (IIT), with respect 
to metabolie control, as well as patients' compli-
ance, and therapeutic safety. We were also inter-
ested in comparing the two different strategies of 
IIT, namely the use of free mixtures of regular 
and intermediate-acting insulin (FMIT) versus the 
multiple insulin injection therapy, which has been 
called "basal and prandial insulin therapy" (BPIT) 
[7]. 
Patients and Methods 
Subjects, Insulin Therapy 
We studied 23 type land 29 type 11 diabetics who 
consecutively started intensified conventional insu-
lin therapy as outpatients between J anuary and 
December 1986. The comparison between the two 
types of treatment (FMIT, BPIT) was based on 
randomized allocation. 
Types of Intensified Insulin Therapy 
FMIT Group (Free Mixture Insulin Therapy). Pa-
tients mixed their combinations of regular and in-
termediate-acting insulin in the syringe, according 
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to the individual demand, immediately before the 
morning and evening injections. Insulin doses were 
chosen according to the algorithms of Holman and 
coworkers [7] and Schiffrin [14], and were modified 
in correspondence to carbohydrate intake and ex-
pected physical activities. If necessary, additional 
regular insulin was injected at dinner or during 
hyperglycemic phases. Some patients had to divide 
their evening injections into preprandial regular 
and bedtime intermediate insulin applications. For 
FMIT only NPH insulin was used as the intermedi-
ate-acting insulin because of the reproducible bio-
availability of regular insulin from these mixtures 
[1]. 
BP IT Group (Basal and Prandial Insulin Therapy). 
Prandial insulin was injected with fountain-pen 
like syringes, containing 100U regular insulin (No-
vopen, Novo), usually thrice a day. The basal insu-
lin requirements were covered with a 24-h-acting 
suspension of human crystalline zinc insulin (UI-
tratard HM, Novo). This long-acting insulin was 
changed to intermediate-acting insulin if necessary. 
Basal insulin was injected into the abdominal sub-
cutaneous fat at 10 p.m. 
The patients were followed up prospectively for 
at least 8 months. 
The c1inical data and the insulin regimens of 
the patients are listed in Table 1. Body weight prior 
to the study period was normal (90%-110% ideal 
body weight [13]) in 62% of the type I group and 
44% of type II. Overweight was noted in 17% of 
type I and 56% of type II patients, and under-
weighted in 21 % of type L 
Inc1usion and Exc1usion Criteria 
The study followed the principles of the Dec1ara-
tion ofHelsinki and each patient gave his informed 
Table 1. Data of the intensive insulin treatment (IlT) outpa-
tients 
Diabetes Insulin 
type therapy 
FMIT+ 
BPIT 
FMIT 
BPIT 
II FMIT+ 
BPIT 
II FMIT 
II BPIT 
n 
23 
12 
11 
29 
18 
11 
Age 
(years/mean 
SD) 
25.6± 6.6 
23.6± 5.5 
27.5± 7.7 
50.7±11.2 
5L7±11.2 
49.7 ± 10.9 
Duration 
of diabetes 
(years) 
1L9±8.9 
9.4±8.7 
12.6±9.0 
8.0±7.1 
8.2±6.5 
7.7±7.7 
FMIT, free mixture insulin therapy; BPIT, basal and prandial 
insulin therapy 
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consent. Before the study, all patients had been 
treated by conventional insulin therapy, i.e., one 
or two daily injections of fixed (industrially pre-
mixed) mixtures, containing 20%-30% regular in-
sulin together with intermediate insulin. All pa-
tients had been referred to our outpatient c1inic 
by other departments of the university hospital or 
by their family doctors because of insufficient met-
abolie control. 
Only those diabetics were inc1uded in the study 
who had been familiar with conventional insulin 
therapy for at least 6 months. Study patients had 
to monitor and document their blood-glucose lev-
els regularly; furthermore, they had to pass a 
1-week ambulatory education pro gram (Table 2). 
Every 4 weeks a visit to the diabetes c1inic was 
obligatory during the follow-up time. Diabetics 
who live alone were exc1uded from the study, as 
were those without a telephone connection. Fur-
ther exc1usion criteria inc1uded gravidity and im-
paired sensation of hypoglycemic symptoms. 
Management of Outpatient Initiation of IIT 
Self-Monitoring Procedures 
One week before IIT started, a member of the dia-
betes team instructed the patient in how to handle 
self-monitoring of blood glucose with color sticks 
(Hämoglucotest 20-800, Boehringer Mannheim). 
Acetonuria and glucosuria had to be monitored, 
whenever the patient suffered from polydipsia and 
polyuria, as weIl as during episodes of fever andjor 
when blood glucose rose to levels of more than 
250 mg/dl. Whenever patients came to see the dia-
betes team, capil1ary blood-glucose levels were 
tested simultaneously by the patient, the nurse, and 
the hospitallaboratory, to compare the results of 
colour sticks, reflectant meter (Reflocheck, Boehr-
inger Mannheim), and a standardized glucose oxi-
dase method. Discrepancies of less than 20% be-
tween the laboratory's and patient's results were 
accepted as accurate self-monitoring. During the 
first 3 to 4 weeks of IIT, blood-glucose monitoring 
was made at least 7 times a day, i.e., before and 
after breakfast, dinner, lunch, and at bedtime. 
During the first week, the patients also tested be-
tween 3 and 4 a.m. 
With respect to hypoglycemia, patients were in-
structed to consume adequate doses and types of 
carbohydrates. The patients' family partners had 
been informed about the correct use of glucagon 
injections in case of hypoglycemia with uncons-
ciousness. 
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Table 2. Curriculum of the educational program for IIT outpatients 
Time 
10a.m. 
-12 a.m. 
12 a.m.-
13.30 p.m. 
13.30 p.m.-
15p.m. 
15 p.m.-
15.30 p.m. 
15.30p.m.-
17.15 p.m. 
Monday Tuesday 
Introduction : Diet: 
problems of Carbohydrate 
the diabetics exchange 
Glycemic index 
offoods 
Problems with 
diet liberalization 
Individual metabolie 
self-monitoring and lunch with the dietician 
Diet: 
Basics on nutrients 
Calculation and 
estimation of 
carbohydrates 
Individual metabolie 
Teehnique of 
Insulin handling 
Injeetion 
Self-monitoring 
self-monitoring and break with the dietician 
Metabolism: 
Basics and 
imbalances 
Insulin: 
Types and action 
Algorithms for 
hypo- and 
hyperglycemia 
The First Weeks of Outpatient IIT 
One week before changing the insulin regimen, pa-
tients beg an to monitor blood glucose. The diabet-
ics had to observe striet1y a standardized diet until 
a stable metabolie eontrol was reaehed. FMIT pa-
tients mixed regular and intermediate insulin by 
themse1ves in the habitual proportions. At the be-
ginning of the 2nd week, the FMIT patients were 
instrueted in how to modify insulin dosages, ae-
eording to the self-monitored data. 
BPIT patients injeeted for the last time the fixed 
mixture on the morning of the new regimen's 1st 
day. Ultratard HM was injeeted at 10 p.m. During 
the first months about 50% to 60% of the daily 
insulin amount was applied in the form of long-
acting insulin, following the algorithms of Holman 
[7]. Subsequently, the doses of basal insulin were 
lowered in favor of the amount of regular insulin. 
The inerease of the Ultratard dosage was not al-
lowed earlier than every 4th to 5th day beeause 
of the saturation eharacteristics of this drug [16]. 
An adequate Ultratard dose is eharaeterized by 
near-identieal blood-glueose levels at bedtime, at 
night, and in the morning. If a patient did not 
reach this stabilization, the long-aeting insulin was 
replaeed by intermediate-aeting insulin injeeted at 
bedtime as weIl. 
Wednesday 
Late complications 
Hygiene 
Drug therapy 
Sports and exercise 
Dietetic produets: 
Ingredients 
Estimation of 
earbohydrates, 
protein, fat 
Insulin adaption: 
Algorithms for 
hypo- and 
hyperglycemia 
Thursday 
Diet: 
Composition 
ofmeals 
outside home 
Alcohol and 
diabetes 
Diet: 
Technique of 
eooking 
Estimation of 
nutrients 
Buffet dinner 
Friday 
Diet: 
Calculation of 
energy intake 
The individual 
diet plan 
Meals during 
travel and illness 
Social problems: 
Professions 
for diabetics 
Family 
Genetics 
Insulin adaption: Final test 
Chan ging the diet; 
in case of 
illness, 
sports, travel 
During the 1st week of the new treatment, the 
patient eame to see the diabetologist every day to 
diseuss the insulin-dosage adaptation. After that, 
a weekly visit was obligatory, until a stable meta-
bolie control was reaehed. In cases of unexpeeted 
or inexplieable hypo- and hyperglyeemia, a 24-h 
telephone service was made available to the pa-
tients. After metabolie stabilization insulin therapy 
and HbA1 levels were eontrolled monthly and a 
liberalization of the diet was allowed: instead of 
fixed times and amounts of earbohydrate intake 
free choice of me al times and free distribution of 
energy substrates over the day were permitted. 
Follow-Up Parameters 
The daily amount of total insulin as weIl as the 
fraction of long-(intermediate-)acting insulin, the 
daily injection frequency, the frequency of hypo-
glycemias (slight hypoglycemias were defined as 
blood glucose levels below 50 mgjdl), and the 
course of body weight were determined. 
A standardized glucose oxidase method was 
used for blood-glucose determination. For the 
HbAl determination an ion exchange chromato-
graphy method (HbA1 Assay, Panehern) was used; 
the normal range in our laboratory was 
5.5%-8.5% of total hemoglobin. 
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Statistics 
Significances of the me an differences of the two 
groups (FMIT vs BPIT) were calculated using Stu-
dent's I-test for unpaired data. The intraindividual 
differences were compared using Student's t-test 
for paired data. For analysis of variance, the Hart-
ley test was used [14]. 
Results 
Details of the follow-up evaluation are shown in 
Tables 3 and 4. All patients of the FMIT group 
used the regimen to which they had been switched, 
for the entire study time. Six of the BPIT patients 
had to change their basal insulin regimen due to 
repeated hypoglycemias. Three patients continued 
with NPH insulin at bedtime (two type II, one 
type I), three patients (all of them type II) injected 
only regular insulin. All BPIT patients injected 
three to four times a day, in contrast to only eight 
of the 30 FMIT patients. 
Frequency of Side EjJects 
During the study period, the frequency of slight 
hypoglycemias per month in diabetic patients of 
type I on FMIT was 9.5 ± 5.6 and on BPIT it was 
10.8±4.9; type II patients on FMIT had 9.9±5.7 
and those on BPIT had 11.2 ± 5.2 episodes per 
Table 3. HbAJ before and during IIT (means + SD) 
Diabetes HbA1 Before vs 2 HbAl 
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month. As only eight of the patients had proto-
colled irregularly hypoglycemic events and glucose 
levels before entering the study, we were not able 
to evaluate the slight hypoglycemias of the preced-
ing time for the whole group. For the eight pa-
tients, the prestudy frequency of slight hypoglyce-
mias was 4.9 ± 3.3 per month. 
Severe hypoglycemia was defined as an episode 
in which the patient was not able to take carbohy-
drates hirnself, but needed the assistance of another 
person. This occurred in one FMIT and one BPIT 
patient, who had to be hospitalized for treatment 
of hypoglycemia with unconsciousness. The FMIT 
patient mistook the evening dose of intermediate 
insulin as regular insulin. The other one suffered 
from primary hyperparathyreoidism; after surgery, 
severe hypoglycemia did not recur. The year before 
entering the study, four ofthe patients had suffered 
from severe hypoglycemias with a total of five epi-
sodes. 
We did not observe any ketoacidosis or hyper-
osmolar nonketotic coma during the study period. 
Courses of HbAl 
After 2 months of intensified insulin therapy, all 
type II diabetics and 21 of 23 type I diabetics had 
significantly decreased HbAllevels compared with 
at the beginning of the study (in type II this was 
66% and in type I 72% of the initial values), inde-
HbA1 
type before IIT and 8 months after 2 months after 8 months 
Therapy (%Hb) (P) IIT 
(%Hb) 
I FMIT 10.8±2.3 <O.OOS 7.4±L1 
I BPIT 9.7±2.2 <O.OOS 7.3±1.2 
II FMIT 10.8±2.0 <O.OOS 7.6±L1 
II BPIT 10.S±2.0 <O.OOS 7.2±1.0 
* P<O.OS 
Table 4. Daily need of insulin before and during IIT (me ans + SD) 
Diabetes 
type 
Therapy 
II 
II 
FMIT 
BPIT 
FMIT 
BPIT 
* P<O.OOOl vs before IIT 
Daily amount of insulin 
(Ujkg BW) 
Before IIT After 4 months * 
0.72±0.3 0.S2±0.2 
0.7S±0.2 0.S1 ±0.2 
0.6S±0.3 0.S2±0.2 
0.78±0.4 0.S6±0.3 
IIT 
(%Hb) 
8.1 ±1.4 
8.6±1.6* 
7.9±1.1 
7.9±1.2 
Basal insulin 
(% of total daily insulin amount) 
Before IIT After 4 months * After 8 months * 
76.8 13.2 69.3±13.7 60.1 ±14.1 
78.0±14.4 S6.6±12.2 42.3± 8.4 
79.0 16.6 69.9±19.3 63.2±17.8 
74.0±1.8.0 S7.1±lS.9 42.1 ±10.8 
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pendently of the type of IIT (Table 3). All type 
II patients were able to keep this glycemic control 
throughout the study time. Four type I had eIe-
vated HbA1 levels after 8 months, compared with 
the initial values (median 107%, range 
102%-118% ofinitial values). 
Daily Demand of Long- and Intermediate-Acting 
Insulin 
The intermediate-(long)-acting insulin amount, 
which was comparable in all patients before IIT 
(about 77% of the total daily insulin amount), de-
creased more with BPIT (to 57% after 4 months 
and 42% after 8 months; means of n= 16) than 
with FMIT (70% after 4 and 62% after 8 months; 
Table 4). 
Courses of Body Weight 
Only three of the type II patients were able to 
reduce their body weight during IIT (to a median 
of 95%, range 87%-99%, of their original body 
weight), and six of the type I patients (to 93%, 
range 89%-97%). Seven of the type I diabetics 
and 12 of the type II patients gained body weight 
(to 105%, range 101 %-107% of original body 
weight in type I, and 107%, range 103%-110%, 
of original body weight in type II). The weight 
changes did not correlate with the courses of 
HbA1, insulin need, or type of treatment. 
Discussion 
This is the first follow-up study to show that the 
change of an insulin regimen from conventional 
to intensified therapy is possible and safe in outpa-
tients. There are eight studies in the literature 
which describe the initiation of insulin therapy in 
newly diagnosed insulin-dependent outpatients 
(for references see [19]). The most striking differ-
ence in results between those studies and ours is 
the level of glycemic control achieved. 
Wilson et al. [19] as weH as Whitehouse et al. 
[18] mention HbA1 levels above 10% after 12, re-
spectively 6 months of treatment. It was our inten-
tion to correct the metabolie situation to near-nor-
moglyeemie levels in our patients. With the excep-
tion of four type I diabetics, all persons fullfilled 
this eriterion with mean HbA1levels of about 8%. 
This is in aecordance with other studies on the 
therapeutic effeet of IIT [5, 17]; none of these re-
sults had been obtained after initiation in outpa-
tients. 
The most relevant acute problem of IIT is the 
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danger of severe, life-threatening hypoglycemia 
[17]. To avoid severe metabolic derangements, 
especially during the initiation phase, very strict 
criteria had to be fullfilled for the patients to enter 
the study. In addition, to get the outpatients accus-
tomed to the new treatment, we changed the habit-
ual proportions of basal and regular insulin very 
slowly (see Table 4). 
The frequency of slight hypoglycemic periods 
usually increases as a consequence of the IIT -in-
duced near-normoglycemia [9]. This was also the 
fact in eight of the investigated patients. Neverthe-
less, the incidence of severe hypoglycemias de-
creased in this group; possibly because of the pa-
tients' regular self-monitoring. 
Nearly all patients succeeded in controlling 
blood-glucose levels much better with intensified 
than with conventional insulin therapy. It may be 
criticized that our study is lacking a control group 
on conventional therapy. A lot of studies have been 
published showing the superiority of IIT over con-
ventional methods [12, 17]. Therefore, it was also 
the aim of our investigation to compare different 
methods of intensified conventional insulin treat-
ment. There is no advantage of the one intensified 
regimen compared with the other with respect to 
the HbA1 levels. The efficacy of IIT depends much 
more on the diabetes type and the individual back-
ground of the patient. The higher portion of basal 
insulin in the FMIT group than in the BPIT group 
has no influence on the incidence of hypoglycemia, 
the course of weight, and the HbA1 levels. It is 
our observation that the main factor for improved 
metabolic control is not the type of IIT, but the 
patient's ability to handle blood glu~ose self-moni-
toring and to modify the dosages of regular insulin 
[8]. 
On the basis of our results we submit that IIT 
is to be recommended not only for type I, but 
also for those insulin-dependent type II patients 
in whom near-normoglycemia is necessary. We 
used IIT in teachable type II diabetics with a longer 
life expectancy (the mean age of the type II study 
group is 50 years). The adequate control of body 
weight after the change from a strict diet to varia-
tions of food intake, which BPIT makes possible, 
seems to be one of the central problems of IIT. 
One-third of our IIT diabetics experienced an un-
desirable increase of body weight, which is in ac-
cordance with the results of Capper et al. [3] and 
of other groups [17], but in contrast to those of 
Chantelau et al. [4]. As a consequence of our re-
sults, we changed our educational program with 
respect to dietetics. We now focus on nutrient ex-
change and variation of meal times much more 
G. Ollenschläger et al.: Outpatient Starting of IIT 
than on food liberalization, as we did before. In 
spite of the increased food intake of several pa-
tients, the me an daily total insulin amount is much 
lower during IIT compared with the conventional 
regimens. Therefore, we presume that the weight 
gain is primarily due to a higher intake of non-
carbohydrate calories, as has been described for 
diabetics during pump therapy [3]. 
The reduced daily total insulin amount is a re-
sult of the decreased dosages of intermediate- and 
long-acting insulin, as weIl as of the accurate insu-
lin adaptation to physical activity. 
In some patients, the kinetics of the long-acting 
insulin are not adequate to the increased insulin 
need during the early-morning phase [16]. In these 
patients, a late bedtime application of intermedi-
ate-acting insulin was able to overcome the blood 
glucose rise in the morning. Otherwise insulin 
pumps, with various basal rates, may be consid-
ered. 
Some type II diabetics needed very little 
amounts of basal insulin during IIT, and could 
be controlled only by regular insulin. Therefore, 
every type II patient should be tested to determine 
whether a basal activity of the endocrine pancreas 
remains. In such cases, preprandial regular insulin 
alone is a very convenient mode of insulin treat-
ment, especially if an insulin pen is used [6, 9]. 
In conc1usion, we were able to demonstrate a 
safe and, with regard to the metabolic control and 
acceptance, efficient way of starting intensified in-
sulin therapy in outpatients. The two discussed 
concepts of IIT are comparable with respect to 
safety and effectivity. The daily basal insulin need 
is much lower with the prandial basal insulin regi-
men compared with the free mixture insulin thera-
py, which may be advantageous, especially in hy-
perinsulinemic diabetics. 
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